Complement Therapeutics doses first patient in Phase 1/Phase 2 Opti-GAIN [...]

Circio Holding ASA, a biotechnology company developing circular RNA-based gene [...]

PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]

OptymEdge has appointed Amy Del Medico as senior director of [...]

Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]

Breye Therapeutics has announced the successful completion of its Phase [...]

Funding will support clinical development of SB-007 and expand pipeline [...]